Purpose: The differentiation between tumor and bland thromboses is important as the management differs. Retrospectively, we aim to evaluate the utility of FDG PET in detecting and differentiating tumor from bland thromboses and if FDG PET provides additional value to contrast-enhanced CT for tumor thrombus detection. Patients and Methods: Twenty-four sites of venous thromboembolism, detected on PET/CT, were retrospectively reviewed. Classification of type of thrombosis was based on histology and radiological follow-up. We evaluated the presence of contrast-enhanced CT findings that were suggestive of tumor thrombosis; sign of invasion, neovascularity, and enhancement. Metabolic activity by means of SUVmax was measured by drawing ROI at the site of thrombosis. Mann-Whitney U test was used to compare the mean SUVmax between thromboses and internal references. We used ROC analysis to identify the optimal cutoff value of SUVmax for detection of tumor thrombosis. Results: Twenty-four sites of venous thromboembolism were identified in 15 patients. All tumor thromboses demonstrated at least 1 positive sign on contrastenhanced CT, whereas 33% of bland thromboses had the same finding. The difference between tumor and bland thrombus SUVmax was statistically significant (P G 0.005). On ROC analysis, a cutoff of SUVmax 2.25 (sensitivity, 78%; specificity, 100%) was suggested to differentiate tumor from bland thrombosis. Conclusion: PET/CT is able to differentiate tumor from bland thrombosis, with an optimal cutoff value of SUVmax 2.25. The metabolic information increases the diagnostic accuracy of tumor thrombus and is a useful adjunct to the described features on contrast-enhanced CT.
P atients with underlying malignancy are predisposed to venous thromboembolism (VTE) secondary to the direct and indirect influences of malignancy on every element of Virchow's triad. With increasing use of imaging as part of disease assessment, there is increasing trend of incidental VTE detection. VTE can be divided into 2 broad categoriesVbland thrombus and tumor thrombus.
Tumor thrombus tends to be associated with solid tumor, including renal cell carcinoma, 1, 2 Wilm tumor, 3 testicular tumor, 4 adrenal cortical carcinoma, lymphoma, 5, 6 pancreatic cancer, 7 osteosarcoma, 8 Ewing's sarcoma, 9 and hepatocellular carcinoma. 10, 11 Tumor thrombosis is an uncommon clinical entity for which the true incidence is unknown. It is estimated that 4% to 10% of renal cell carcinoma are associated with venous tumor thrombosis in the renal vein or inferior vena cava, 12 and a higher incidence of 20% to 30% are found in hepatocellular carcinoma. 10, 11 The prognostic value of the presence of tumor thrombosis varies according to different tumor types; for example, portal vein tumor thrombosis in hepatocellular carcinoma is a poor prognostic factor, as surgical resection and transcatheter arterial chemoembolization lack the desired therapeutic results, 10, 11 whereas no impact on survival has been demonstrated in nephroblastoma with intracaval or atrial tumor thrombus. 13 However, consensus agrees that the primary treatment for tumor thrombosis should be surgical thrombectomy, if possible, or chemoradiation, although there is no role of anticoagulation therapy. Therefore, it remains important to be able to identify and differentiate tumor thrombosis from bland thrombosis to avoid the unnecessary use of anticoagulation, which carries the inherent risk of bleeding complications.
There are several contrast-enhanced CT features, previously described, which are suggestive of tumor thrombosis. 14, 15 These include direct or contiguous invasion from tumor or metastasis (sensitivity of 32% and 62%, respectively), neovascularity (sensitivity 43%, specificity 100%), and generalized intrathrombus enhancement (sensitivity 83%). 14 Dramatic venous expansion of portal vein in hepatocellular carcinoma has also been described, 14 and the cutoff mean diameter of 23 mm or greater would give rise to 86% sensitivity and 100% specificity in CT detection of tumor thrombosis.
Although there are a handful of case reports, 16Y25 there are only 3 small retrospective series 26Y28 that investigated the usefulness of 18 fluoro-deoxyglucose positron emission tomography (FDG PET) in detection of tumor thrombus; all concluded that FDG PET can differentiate tumor thrombosis from bland VTE based on SUV. Sharma et al 28 suggested a cutoff value of maximum standardized uptake value (SUVmax) of 3.63 with sensitivity yield of 72% and specificity of 90%. None of these series have compared the accuracy of the 2 modalities, FDG PET and contrast-enhanced CT, in differentiating tumor from bland thrombus. We aim to investigate the use of FDG PET in detecting and differentiating tumor from bland thrombus by means of SUVmax and evaluate if FDG PET provides additional information to contrast-enhanced CT for tumor thrombus detection in a cohort of patients who underwent FDG PET/contrast-enhanced CT (PET/CT).
PATIENTS AND METHODS
The local institutional research and ethics review board approved this retrospective study.
Patients
Patients with VTE detected by PET/CT were identified through our database from March 2007 to May 2011. Demographic data, types of malignancy, clinical outcomes, and follow-up imaging studies were recorded. injection. 18 F-FDG dosage was weight based: weight (kg) Â 0.13 mCi. PET/CT was acquired using dedicated PET/CT scanner (Discovery VCT; 64 MSCT, GE Healthcare Bio-Sciences Corp., Piscataway, NJ) 60 minutes after 18 F-FDG injection. Contrast-enhanced CT protocol was as follows: 120 kVp; 200 to 400 mA; field of view, 50 cm; pitch, 0.984:1; intravenous contrast medium (1.5 mL/kg) with injection rate of 2.0 mL/s; performed 70 seconds after intravenous contrast injection in the portovenous phase. Attenuation correction for PET data using CT images was performed, and images were reconstructed using an ordered-subset expectation maximization iterative algorithm (14 subsets and 2 iterations). All PET/CT studies were retrospectively reviewed by an experienced radiologist, trained to report PET/CT, and blinded to the clinical or radiological followup data.
Sites of thromboses were identified on contrast-enhanced CT; CT features that were suggestive tumor thrombosis, that is, direct or contiguous invasion from tumor, neovascularity within the thrombus, and generalized intrathrombus enhancement based on visual analysis were documented in both studied groups. Neovascularity and intrathrombus enhancement were assessed qualitatively based on visual analysis as no noncontrast CTwas performed as part of the PET/CT examination protocol. As venous expansion was only studied in the portal vein previously, 14 there were various VTE sites involvement in our cohort and not exclusively confining to the portal veins, therefore, venous expansion was excluded from statistical analysis. Area of focal hypermetabolic activity corresponding to site of thrombus was measured using region of interest (ROI) by means of SUVmax; if no focal 18 F-FDG uptake was identified, the ROI was manually placed over the site of thrombosis for SUVmax measurement ( Fig. 1 ). These were categorized into tumor thrombosis uptake (tSUVmax) and bland thrombosis uptake (bSUVmax) according the criteria set below based on histology or follow-up imaging. Mediastinal blood pool uptake (mSUVmax) and background liver uptake (lSUVmax) were taken as internal references.
Results Interpretation
Histological confirmation was taken as the gold standard when available. In the cohort without histological correlations, thrombus that resolved after anticoagulation therapy, was regarded as bland thrombus; whereas, progression of thrombus on follow-up imaging was regarded as indirect marker of tumor involvement.
Statistics
Mean T standard deviation and range were used as descriptive statistical analysis. The mean SUVmax of mediastinal blood pool, liver background, tumor, and bland thromboses were compared using Mann-Whitney U test for nonparametric data. Receiver operating characteristic curve (ROC curve) was produced to identify an optimal cutoff value of SUVmax to differentiate tumor thrombus from bland thrombus. All statistical analyses were performed using the statistical package SPSS for Windows (Version 11.0, SPSS, Chicago); P G 0.05 was considered to indicate statistical significance.
RESULTS

Patients
Forty patients were identified to have VTE from our database; only 15 patients had histological confirmation and imaging follow-up to determine the nature of VTE. Therefore, 15 patients were included in the study analysis. There were 7 male and 8 female subjects with a mean age of 62.7 years (median, 58.5 years; range, 46Y76 years). All 15 patients had known primary malignancies, and PET/CT scans were performed for staging/restaging or treatment evaluation. Five patients had more than one site of VTE, giving rise to 24 sites of VTE for analysis. Demographic characteristics of the patients were tabulated in Table 1 .
None of the above patients had concurrent inflammatory conditions at the time of PET/CT, therefore minimizing the possibility of thrombophlebitis or pylephlebitis, which can give rise to increased metabolic activity, 29 as cause of hypermetabolic thrombus.
Classification of Thromboses
There were 18 sites of tumor thromboses and 6 sites of bland thromboses.
Eight VTE sites had histological confirmation (Fig. 2) , whereas 16 sites had imaging follow-up in the form of PET/CT, MRI, contrast-enhanced CT (Fig. 3) , and US Doppler studies. The mean follow-up period was 143 T 104 days (range, 16Y365 days).
PET/CT
Among the 18 sites of tumor thromboses, direct invasion from tumors or metastases was present in 5 sites and contiguous spread in 10 sites, whereas the remaining 3 sites were remote from the tumors or metastases. On contrast-enhanced CT, 7 sites (39%) demonstrated intrathrombus neovascularity based on visual analysis, and 9 sites (50%) had inhomogeneous intrathrombus enhancement ( Table 1) .
All 6 bland VTE sites (100%) were remote from tumors or metastases, and none showed neovascularity. Two bland thromboses demonstrated intrathrombus enhancement based on visual analysis.
The mSUVmax and lSUVmax, as internal references, showed no statistical significance between tumor thrombosis and bland thrombosis (P = 0.734 and P = 0.865, respectively). The differences between tSUVmax, and mSUVmax and lSUVmax were statistically significant (both P G 0.001). The mean SUVmax for bland thrombosis group was 1.5 T 0.5 (range, 0.7Y2.0), and the mean SUVmax for tumor thrombosis group was 4.5 T 4.5 (range, 1.0Y14.8).
The difference between bSUVmax and tSUVmax was statistically significant (P = 0.005) ( Fig. 4) .
On ROC analysis, a cutoff SUVmax of 2.25 will yield 78% sensitivity and 100% specificity, in differentiating tumor thrombosis from bland thrombosis (Fig. 5 ).
If this is corrected against the mediastinal blood pool uptake (tSUVmax/mSUVmax), ROC analysis showed that a cutoff ratio of 1.58 will produce sensitivity of 83% and specificity of 100% (Fig. 6 ).
If the 3 outliers within the tumor thrombosis group were excluded (SUVmax, 13.3, 14.2, and 14.8; Fig. 4 ), the ROC analysis produced similar results, and the optimal cutoff SUVmax of 2.25 remained unchanged (Fig. 7) .
In the 2 bland thromboses that exhibited intrathrombus enhancement, the metabolic uptake was less than SUVmax 2.25 (SUVmax 1.9 and SUVmax 2.0, respectively). Therefore, FDG PET using SUVmax cutoff of 2.25 changed the contrast-enhanced CT diagnosis in 33% of bland thromboses.
DISCUSSION
Previously described CT features that help to differentiate tumor from bland thrombus 14, 15 include direct invasion from tumor and neovascularity within the thrombus, whereas generalized thrombus enhancement and contiguous spread can be helpful to increase diagnostic confidence. Our results agreed with previous published data. 14 The lower incidence of intrathrombus neovascularity found in our study could be explained by acquisition of CT images during the venous phase as neovascularity is easier to detect in early arterial phase of the contrast dynamic.
Previous 3 retrospective series 26Y28 using PET/ unenhanced CT have suggested that the metabolic uptake within the thrombus can be used to detect tumor thrombosis. Summary of these three studies were tabulated in Table 2 .
The FDG avidities in the primary tumors varied in this cohort composed of heterogeneous types of tumors. Previous study has demonstrated positive correlation between the level of uptake in the primary tumor and tumor thrombus. 28 Therefore, there is no surprise that the range of tSUVmax varied considerably.
The ROC analysis identified that a cutoff of SUVmax 2.25 can be used to differentiate tumor from bland thrombosis with sensitivity of 78%, specificity of 100%, and accuracy of 88%.
Using this cutoff value, all the bland thromboses that had CT features of intrathrombus enhancement could be excluded, thus increasing the specificity of PET/CT.
Tumor thrombosis commonly develops from direct or contiguous spread from the primary tumor or metastasis. The process could involve intraluminal extension of the tumor without invasion of the vascular endothelium or direct invasion into the segment of venous circulation. The presence of endothelial invasion tends to preclude successful surgical thrombolectomy, and the risk of tumor spread is higher. This may partly explain why the presence of tumor thrombosis has different prognostic impact on different carcinomas. For example, hepatocellular carcinoma commonly invades the portal vein producing tumor thrombosis and is associated with poorer outcome. In renal cell carcinoma, tumor thrombus can propagate into the renal vein and inferior vena cava without invasion of the vascular endothelium. Therefore, if the tumor thrombus can be successfully resected, it will not be of any prognostic significance in patient's survival. 30 In our study, contrast-enhanced CTwas performed sequentially with FDG PET. Although there has been concern regarding the impact of IV contrast on CT-based attenuation correction, especially in regions of dense IV contrast, 31 this study assessed regions of relatively lower IV contrast concentration in the venous circulation (performed at 70 seconds after IV contrast injection) and, therefore, is not expected to significantly affect the CT-based attenuation coefficient. 32 This study has several limitations. The study includes a heterogeneous group of tumors, which have different FDG avidities and, hence, the varied FDG uptake in the tumor thrombus. The lack of true gold standard in some of the cases may also introduce bias into the analysis of this study, as histological confirmation was only limited to 8 VTE sites. The sample number is small, although the results were of statistical significance, despite the small numbers. We agree with previous authors 28 that larger study is required and ideally with histological validations of the diagnoses.
CONCLUSION
The measurement of SUVmax on FDG PET is of additional value to contrast-enhanced CT in differentiating tumor thrombosis from bland thrombosis, especially in excluding the presence of tumor thrombosis using SUVmax cutoff value of 2.25. This information will enhance the accuracy of scan interpretation especially with the increasing use of diagnostic contrast-enhanced CT together with FDG PET, as a ''one-stop shop.'' 27 11 PET/unenhanced CT Histology, imaging and clinical follow-up No SUV measurements. Visual analysis found uptake to be a useful sign in differentiating tumor thrombus from benign thrombus. This further characterized suspicious thrombotic lesions detected on contrast-enhanced CT previously. Sharma et al 28 24
PET/unenhanced CT Histology, imaging follow-up SUVmax cut-off 3.63 was suggested to differentiate bSUVmax and tSUVmax with sensitivity 71.4% and specificity 90%.
